YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, that is now interchangeable [1] Interchangeable designation of YUFLYMA® is supported by positive data from the Phase III interchangeability study in patients with...
Read More Details
Finally We wish PressBee provided you with enough information of ( U.S. FDA grants interchangeable designation to YUFLYMA® (adalimumab-aaty), Celltrion's biosimilar to Humira® (adalimumab) )
Also on site :
- What to know about the trial of an ex-Michigan cop charged in the killing of a Black motorist
- Trump sees no red line that would change tariff policy - The Atlantic
- Pope Tawadros meets with mayor of Polish town